Abstract
Cervical cancer is a common malignant tumor in the female reproductive system. High-risk human papillomavirus (HPV) persistent infection is a major risk factor for cervical cancer. After curative effects of conventional radiotherapy and chemotherapy and traditional surgery on cervical caner were limited, immunotherapy and immunotherapy have become hotspots in medical research. In recent years, significant progress has been made in the research of cervical cancer preventive vaccines. Therapeutic vaccines such as DNA vaccine, recombinant vector vaccine and anti-PD-1 monoclonal antibody have also achieved staged research results. The efficacy of immunotherapy for advanced stage, previous treatment failure, advanced stage, and recurrent cervical cancer is the current direction of clinical research. Key words: Cervical cancer; Human papillomavirus vaccine; DNA vaccine; Anti-PD-1 monoclonal antibody
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
